Latest Report on China Avian Influenza Vaccine Industry 2013-2017

The report “Research Report on China Avian Influenza Vaccine Industry, 2013-2017″ by China Research and Intelligence is now available at Chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Research Report on China Avian Influenza Vaccine Industry, 2013-2017 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Life Sciences’ market research reports has a new addition of “Research Report on China Avian Influenza Vaccine Industry, 2013-2017”On chinamarketresearchreports.com. In the current stage, many countries choose to cull all infected poultry to control avian influenza, instead of immunizations. The total volume of the poultry in China is over 10 billion, but more than 90% raisers only have less than 2,000 broilers. In case of epidemic diseases, it is hard to control them, which will result in huge losses. Therefore, it is quite necessary to immunize the poultry with avian influenza vaccines.
Avian influenza vaccines have been used for more than 10 years in China. More than 10 years ago, some poultry raising farms in China used the H5N1 avian influenza vaccine. They were not forced but voluntary to use vaccines. Between 2001 and 2005, when China avian influenza vaccine industry just started, various problems frequently emerged. To resolve these problems, Ministry of Agriculture of China set up an entry barrier of the avian influenza vaccine producing market and tightly supervised it. It established strict regulations on the production and sales of avian influenza vaccines. For example, avian influenza vaccines must be produced in workshops that are in compliance with GMP and must be inspected every year. 

Buy a copy of this report by China Research and Intelligence @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114649  .

In China, the subsidy provided by the government over culling the infected poultry is CNY 10 per bird. In case serious epidemic diseases occur, the subsidy amount will be higher.

In 2012, the live stock volume of laying hens in China was about 1.45 billion, and that of broilers was approximate to 10 billion. The output volume of eggs in China was 28.61 million tons in 2012, increasing by 1.76% YOY. According to National Compulsory Immunization Plan of Animal Epidemic Diseases 2013 issued by Ministry of Agriculture of China, the government conducts compulsory immunizations against 4 diseases, including highly pathogenic avian influenza. The government is responsible for appropriations. In 2012, the scale of China avian influenza vaccine market was over CNY 1 billion.

With the increasing living standards of Chinese people, the demand for eggs and poultry meat is growing accordingly. In China and other neighboring countries, avian influenza, especially highly pathogenic avian influenza, has not been effectively controlled yet. For example, H5N1 highly pathogenic avian influenza out broken in North Korea in May 2013. In addition, besides H5N1, H5 and H7 subtype highly pathogenic avian influenza are also possible to outbreak.

Therefore, it is predicted that the scale of China avian influenza vaccine market will keep increasing and many animal healthcare enterprises will attach attention to this market. 

Complete report spread across [30] pages available @ http://www.chinamarketresearchreports.com/114649.html . Read more on “Research Report on China Avian Influenza Vaccine Industry, 2013-2017” report below.

Through this report, the readers can acquire the following information:
- Incidence status of avian influenza
- Poultry raising status in China
- Policy environment and government procurement of avian influenza vaccines in China
- Supply and demand status of China avian influenza vaccines
- Major avian influenza vaccine producing enterprises in China and their performance
- Perspective of China avian influenza vaccine industry

The following enterprises and people are proposed to purchase this report:
- Animal vaccine production /trade enterprises
- Poultry raising enterprises
- Management organizations of livestock husbandry industry
- Investors and research institutes concerned about the avian influenza vaccine industry

For further information on “Research Report on China Avian Influenza Vaccine Industry, 2013-2017” report OR for any other business research / market intelligence need on the ‘Life Sciences’ market (http://www.chinamarketresearchreports.com/cat/life-sciences.html .), contact sales@chinamarketresearchreports.com / Call +1 888 391 5441.

RnRMarketResearch: Seasonal Influenza Vaccine Market 2018 in Asia-Pacific

GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 – Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines.

Get Report Details @ http://www.rnrmarketresearch.com/seasonal-influenza-vaccine-market-in-asia-pacific-to-2018-positive-impact-of-government-support-offset-by-limited-production-capacity-high-investment-and-strict-regulations-as-barriers-to-new-entra-market-report.html

The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented. Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region. GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 9% during the period 2011–2018 from $1,015m in 2011 to $1,879m by 2018. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies. GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2011–2018. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts. GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.

Scope

The report analyses vaccination patterns, market characterization, regulatory landscape, pipeline analysis, competitive landscape and key M&A trends in the seasonal influenza vaccine market in the APAC region.
The report covers
Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
Market forecasts for the seasonal influenza vaccines from 2011 to 2018
Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
Key drivers and restraints that have created significant impact on the market.
Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2012 in the seasonal influenza vaccine market.

Reasons to Buy

The report will aid business development and marketing executives strategizing their product launches:
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=89199